Aleix Prat

@prat_aleix

head medical onc , head translational genomics and targeted therapeutics in solid tumors and chair Tweets and opinions are mine

Vrijeme pridruživanja: svibanj 2017.

Tweetovi

Blokirali ste korisnika/cu @prat_aleix

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @prat_aleix

  1. proslijedio/la je Tweet
    4. velj

    Coneixes el programa d’atenció compartida del de mama entre l' i l'? L’objectiu de la iniciativa és millorar la qualitat de vida de les més de 100 dones que hi participen amb mesures com un seguiment especialitzat

    Poništi
  2. prije 18 sati

    Solo la investigacion clinica y traslacional nos permitira avanzar mas rapido en el tratamiento del cancer — un conjunto de enfermedades cuya incidencia y prevalencia aumentaran considerablemente en la proxima decada si o si

    Poništi
  3. proslijedio/la je Tweet
    prije 21 sat
    , , i još njih 5
    Poništi
  4. prije 22 sata

    Inscripciones abiertas! Os esperamos el 15-20 de marzo 2020 en Lloret de Mar. Organiza: Dr. Aureli Torné y Dr. Jaume Pahisa

    Poništi
  5. proslijedio/la je Tweet
    Poništi
  6. proslijedio/la je Tweet

    On the is launching the to fight cancer through research. Standing together we can beat it.

    Poništi
  7. proslijedio/la je Tweet
    4. velj

    Hoy, reivindicamos la importancia de la investigación académica y traslacional para definir nuevos horizontes clínicos.

    , , i još njih 7
    Poništi
  8. 4. velj

    Job offer at Dr. Tutt’s Lab — Post Doctoral Clinical Training Fellow - Target Validation & DNA Damage Repair Laboratory - ICR

    Poništi
  9. 2. velj

    I also recommend reading

    Prikaži ovu nit
    Poništi
  10. 2. velj

    I personally do not understand how a trial designed to see if chemo can be spared in the intermediate risk group (i.e. RS 11-25) and fails to identify the group with intermediate risk (only 2% distant recurrences at 5 years and 5% in 9 years), can be called "practice changing"

    Prikaži ovu nit
    Poništi
  11. 2. velj

    Interesting thoughts from regarding TailorX + MINDACT trials:

    Prikaži ovu nit
    Poništi
  12. proslijedio/la je Tweet
    1. velj

    X Jornada de Càncer de Pulmó a .Aqui teniu el programa, si esteu interessats ens veiem el 28 de Febrer.

    Poništi
  13. proslijedio/la je Tweet
    31. sij

    ¿Nos conoces? Somos un grupo académico de investigación de referencia en que desarrolla ensayos clínicos de excelencia. Actualmente tenemos más de 400 socios investigadores más de 100 centros de España, Portugal, Francia e Italia. 👉

    Poništi
  14. proslijedio/la je Tweet
    31. sij

    Many thanks Aleix for joining the EU consortia. Great things will come up in this collaborative project.

    Poništi
  15. proslijedio/la je Tweet
    30. sij

    491 days after presented at conference, the trial is published! Many interesting things.... And finally, the ans to the question of whether this "saves lives" (thread)

    Prikaži ovu nit
    Poništi
  16. proslijedio/la je Tweet
    29. sij

    Hoy se ha publicado la "SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)", con la colaboración de y

    Poništi
  17. proslijedio/la je Tweet
    29. sij

    Gran èxit avui de la jornada Ballar pel teu Benestar. #oncor#oncologia@amics del clinic@hospital clinic

    Poništi
  18. proslijedio/la je Tweet
    29. sij

    That was great!!! and thanks for the very nice talk on Tuesday

    Poništi
  19. proslijedio/la je Tweet
    29. sij
    Odgovor korisnicima i sljedećem broju korisnika:

    It was great to meet you three and learn from your spectacular work. We look forward to the next meetings and to collaborate with you

    Poništi
  20. 29. sij

    Coming back from Oslo with and after the intense kick-off 2-day meeting of the RESCUER breast cancer project, a H2020 EU project of 6M euros led by at the Univ. Oslo — Very happy to participate from

    Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·